Delve Health has announced a collaboration to integrate AliveCor's KardiaMobile 6L personal EKG device into its LiveCare Link + smart RPM gateway to improve cardiac care.

This partnership aims to enhance research, expedite drug development processes and offer treatments for unmet medical needs, ultimately improving patient outcomes in cardiology.

Delve Health’s solution supports data-driven decision-making and provides remote patient management leading to targeted care.

AliveCor's US Food and Drug Administration (FDA)-cleared KardiaMobile 6L is designed to provide instant detection of various heart rhythms. It is used by cardiologists to measure the QT interval, a significant risk factor for certain medications and congenital issues.

By integrating Delve Health's platform with AliveCor's KardiaMobile device, the partnership addresses challenges in digital healthcare by passively collecting real-world data (RWD) and real-world evidence (RWE).

Utilising the KardiaMobile 6L, patients and healthcare professionals can monitor heart rhythms and identify abnormalities such as atrial fibrillation in real-time.

The data can be sent to healthcare providers through Delve Health's Clinical StudyPal platform, enabling timely feedback for clinical trials and quick interventions.

This integration facilitates more efficient clinical trials by reducing burdens on sites and patients, allowing sponsors to make informed decisions quickly based on real-time data.

Delve Health founder and CEO Wessam Sonbol said: “This collaboration aligns perfectly with our mission of transforming healthcare through data-driven insights.

“By combining our fully customisable, end-to-end platform with AliveCor's KardiaMobile, a cardiology-specific medical device, we can make significant strides in improving patient care and positively impacting global health outcomes.”

Last year, healthcare technology company PaceMate partnered with AliveCor to combine the strengths of the PaceMateLIVE platform with AliveCor’s KardiaPro platform.